After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet ...

Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Arcus Biosciences (RCUS – Research Report) today and set a ...

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...

Shares in iTeos Therapeutics dropped over 20% despite positive interim data from the GALAXIES Lung-201 Phase II study with ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...